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Abstract
Introduction: The immune responses in patients with novel A(H1N1) virus infection (nvA(H1N1)) are incompletely
characterized. We investigated the profile of Th1 and Th17 mediators and interferon-inducible protein-10 (IP-10) in
groups with severe and mild nvA(H1N1) disease and correlated them with clinical aspects.
Methods: Thirty-two patients hospitalized with confirmed nvA(H1N1) infection were enrolled in the study:
21 patients with nvA(H1N1)-acute respiratory distress syndrome (ARDS) and 11 patients with mild disease. One
group of 20 patients with bacterial sepsis-ARDS and another group of 15 healthy volunteers were added to
compare their cytokine levels with pandemic influenza groups. In the nvA(H1N1)-ARDS group, the serum cytokine
samples were obtained on admission and 3 days later. The clinical aspects were recorded prospectively.
Results: In the nvA(H1N1)-ARDS group, obesity and lymphocytopenia were more common and IP-10, interleukin
(IL)-12, IL-15, tumor necrosis factor (TNF)a, IL-6, IL-8 and IL-9 were significantly increased versus control. When
comparing mild with severe nvA(H1N1) groups, IL-6, IL-8, IL-15 and TNFa were significantly higher in the severe
group. In nonsurvivors versus survivors, IL-6 and IL-15 were increased on admission and remained higher 3 days
later. A positive correlation of IL-6, IL-8 and IL-15 levels with C-reactive protein and with > 5-day interval between
symptom onset and admission, and a negative correlation with the PaO2:FiO2 ratio, were found in nvA(H1N1)
groups. In obese patients with influenza disease, a significant increased level of IL-8 was found. When comparing
viral ARDS with bacterial ARDS, the level of IL-8, IL-17 and TNFa was significantly higher in bacterial ARDS and IL-
12 was increased only in viral ARDS.
Conclusions: In our critically ill patients with novel influenza A(H1N1) virus infection, the hallmarks of the severity
of disease were IL-6, IL-15, IL-8 and TNFa. These cytokines, except TNFa, had a positive correlation with the
admission delay and C-reactive protein, and a negative correlation with the PaO2:FiO2 ratio. Obese patients with
nvA(H1N1) disease have a significant level of IL-8. There are significant differences in the level of cytokines when
comparing viral ARDS with bacterial ARDS.
Introduction
Originating from Mexico and spreading initially in the
United States and Canada, a novel influenza A(H1N1)
virus infection (nvA(H1N1)) of swine origin spread glob-
ally during spring 2009 to mid-February 2010. Rates of
hospitalization and death have varied widely according
to country [1]. Among hospitalized patients 9 to 31%
have been admitted to intensive care units (ICUs) where
the rate of death was 14 to 46% [2-6].
In Romania the pandemic wave lasted from September
2009 to February 2010, reaching a peak in December.
The Romanian Ministry of Health reported 7,008 con-
firmed cases of nvA(H1N1) influenza, the death rate
being 1.9%.
Primary influenza pneumonia had a high mortality rate
during pandemics not only in immune-compromised
individuals and patients with underlying co-morbid con-
ditions, but also in young healthy adults [7].
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clinical studies have identified dysregulated systemic
inflammation as an important pathogenetic mechanism
correlating with severity and progression of the disease
[8,9]. The role of most immune responses in controlling
and clearance of H1N1 influenza A or its contribution
to severe respiratory compromise is not well known.
To and colleagues found higher plasma levels of
proinflammatory cytokines and chemokine in the group
of patients with acute respiratory distress syndrome
(ARDS) caused by viral A(H1N1) influenza, throughout
the initial 10 days after symptom onset [8]. Bermejo-
Martin and colleagues found that mediators involved in
the development of Th17 cells (IL-6, IL-8, IL-9, IL-17),
Th1 cells (TNFa, IL-15, IL-12p70) and type II interferon
(IFNg) had high systemic levels in hospitalized patients
with nvA(H1N1) influenza [9]. The detrimental or bene-
ficial role of these cytokines in severe illness is not
known.
The aim of our study was to further investigate the
profile of Th1 and Th17 mediators and interferon-
inductible protein-10 (IP-10), an innate-immunity med-
iator, as early host response in a group of critical and
noncritical hospitalized patients with nvA(H1N1) from
Cluj-Napoca, Romania, and to correlate them with the
clinical aspects.
Materials and methods
Patients and controls
The study was performed between October 2009 and
February 2010 in the ICUs of the Emergency County
Clinical Hospital and of the Teaching Hospital of Infec-
tious Diseases, Cluj-Napoca, Romania.
Thirty-two patients hospitalized with nvA(H1N1)
infection were enrolled in the study: 21 patients with
nvA(H1N1)-ARDS, and 11 patients with nvA(H1N1)-
mild disease. Additionally, 20 patients with bacterial
sepsis-ARDS were included and served to compare the
cytokine levels between the nvA(H1N1)-ARDS group
and the bacterial sepsis-ARDS group.
The study protocol was approved by the Ethics Com-
mittee for Clinical Research of the University of Medi-
cine and Pharmacy ‘Iuliu Hatieganu’ Cluj Napoca and
the hospital authority. Informed consent was obtained
from each patient or their legal representative.
The inclusion criteria were age > 16 years, symptoms
compatible with influenza and confirmed nvA(H1N1)
virus, bacterial severe sepsis with ARDS, and informed
consent. The exclusion criteria were age < 16 years,
known infection by human immunodeficiency virus,
patients with other respiratory viral infections, bacterial
sepsis without ARDS-syndrome, and refusal to consent.
The control group included 15 healthy volunteers
without chronic or acute disease.
Data were recorded prospectively by investigators at
each hospital. The following data were recorded: age,
sex, pregnancy, underlying diseases (chronic obstructive
pulmonary disease, asthma, diabetes, chronic heart fail-
ure, chronic renal failure, cirrhosis, immunosuppres-
sion), obesity defined as body mass index > 30, and the
time in days from symptom onset to hospital admission.
Hematological, biochemical and microbiological results
were included in the database. The extension of lung
infiltrates on chest X-ray scan was registered as the
number of quadrants involved. The severity and prog-
nosis of the illness was assessed in adults using the
Acute Physiology and Chronic Health Evaluation II
(APACHE II) score and the Sepsis-related Organ Failure
Assessment (SOFA) score. ARDS was defined using the
1994 American-European Consensus Conference defini-
tions [10]. The pulmonary dysfunction score was based
on the PaO2:FiO2 ratio, ranging from 0 to 3 where
grade 0 represented a ratio less or equal to 250; grade 1,
a ratio ranging from 250 to 175; grade 2, a ratio ranging
from 100 to 175; and grade 3, a ratio less or equal to
100 [11].
A(H1N1) influenza virus presence was confirmed by
testing nasopharyngeal swabs or bronchoalveolar lavage
specimens with real-time PCR (commercial kits: Full
Velocity SYBR Green QRT-PCR/SuperScript III Plati-
num One-Step Quantitative RT-PCR Taqman; Invitro-
gen Corporation, Carlsbad, California, USA) at The
National Influenza Centre of Cantacuzino Institute,
Bucharest, Romania.
Cytokine and chemokine quantification
In patients with nvA(H1N1)-mild disease, the serum
samples were taken on hospital admission. In patients
with nvA(H1N1)-ARDS infection, the serum samples
were taken on admission to the ICU and 3 days later to
determine cytokine kinetics. The installation of ARDS,
either viral or bacterial, in the course of the disease
determined the time of admission to the ICU. In
patients with bacterial sepsis-related ARDS, the serum
samples were taken on admission to the ICU.
The enrolled patients and the healthy volunteers gave
whole blood, which was clotted for 30 minutes at 37°C
a n ds t o r e da t- 7 0 ° Cu n t i lu s e .T h er e s u l t i n gs e r u mw a s
used for cytokine determination.
Seven different serum cytokines (IL-6, IL-8, IL-
12p70, IL-15, IL-17, TNFa and IFN-g)w e r em e a s u r e d
with Luminex 200 (Luminex Corporation, Austin, TX,
USA) using a multiplex cytokine kit along with the
assay performed in accordance with the manufacturer’s
instructions (R&D Systems, Minneapolis, MN, USA).
Additionally, we used ELISA kits for quantitative
determination of the two cytokines IL-9 and IP-10
(Quantikine; R&D Systems).
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Subjects were stratified into three groups: 11 patients
with nvA(H1N1)-mild disease, 21 patients with nvA
(H1N1)-ARDS, and 20 patients with bacterial sepsis-
ARDS.
Descriptive statistics included means and standard
deviations or medians and interquartile ranges for con-
tinuous variables of normal and non-normal distribu-
tions. Clinical and biochemical characteristics and
cytokine levels were compared. The Fisher exact test
and the chi-square test were used for categorical vari-
ables. The Mann-Whitney U test was used for nonpara-
metric variables. The Wilcoxon test (nonparametric test)
was used to compare two paired groups. The association
between nonparametric variables was determined by the
Spearman correlation coefficient (r). Any value of P <
0.05 was considered statistically significant. GraphPad
Prism version 5.03 Software for Windows (GraphPad
Software, La Jolla, California, USA) was used.
Results
A total of 32 patients with confirmed nvA(H1N1) infec-
tion and 20 patients with bacterial sepsis-ARDS were
enrolled over the study period. Their demographic,
co-morbidities and clinical characteristics are presented
in Table 1. Patients in the nvA(H1N1)-ARDS group were
significantly older than those in the nvA(H1N1)-mild dis-
ease group (median age 42 years vs. 33 years, P =0 . 0 0 9 ) .
Obesity was more common in the nvA(H1N1)-ARDS
group. The median interval between onset of illness and
admission was 6 days (interquartile range 3.5 to 8.5) in
the nvA(H1N1)-ARDS group and 2 days (interquartile
range 2 to 3) in the mild disease group (P < 0.001)
(Table 1). All the patients with nvA(H1N1) virus infec-
tion presented symptoms of acute respiratory viral infec-
tion on admission. The median length of hospital stay
was higher in the nvA(H1N1)-ARDS group compared
with the mild disease group (11 days vs. 6 days, P <
0.001). All patients with nvA(H1N1) virus infection
received oseltamivir on admission: the standard dose
(150 mg/day) was administered for patients with mild
disease, and a higher dose (300 mg/day) was used for
nvA(H1N1)-ARDS patients. During the ICU hospitaliza-
tion, critical patients with influenza virus infection
(ARDS) received corticosteroid therapy (hydrocortisone
or methylprednisolone). In agreement with our protocol,
empirical antibiotics were started on admission.
Among 21 patients with nvA(H1N1)-ARDS, four
developed acute renal failure requiring renal replace-
ment therapy, two developed secondary bacterial pneu-
monia and three developed pneumothorax (Table 1).
Ten patients from the nvA(H1N1)-ARDS group received
non-invasive ventilation and 11 patients received
mechanical ventilation.
Pregnancy was another risk factor for nvA(H1N1)-
ARDS infection and ICU admission (3/21 cases; Table
1). Two pregnant women were in the third trimester
and one was in the second trimester. No underlying dis-
ease was noted. The range interval after symptom onset
and ICU admission was 3 to 7 days. Caesarean delivery
was necessary in two cases. All pregnant women
required respiratory support (two invasive and one non-
invasive) during hospitalization and all survived.
Seven patients died in the nvH1N1-ARDS group.
Histopathological changes were similar in all cases: tra-
cheitis, bronchitis with focal squamous metaplasia,
necrotizing bronchiolitis, emphysema, extensive diffuse
alveolar damage associated with alveolar hemorrhage
and marked hyaline membrane formation, fibrosis and
granulocyte pulmonary infiltrates. Pulmonary throm-
boemboli with focal infarcts were observed in three
cases.
The lymphocyte count was significantly lower in the
nvA(H1N1)-ARDS group than in the mild disease group
(P = 0.011) (Table 2). Comparing laboratory abnormal-
ities on hospital admission we found that patients with
nvA(H1N1)-ARDS were more likely to have elevated
levels of serum lactate dehydrogenase, alanine and
aspartate aminotransferase (P <0 . 0 0 1 ,P = 0.049 and
P < 0.001, respectively) than patients with nvA(H1N1)-
mild disease (Table 2).
Twenty patients with bacterial sepsis-ARDS were
included to compare the cytokine levels in viral and bac-
terial ARDS. Immune suppression (six patients with
cancer) was more common in the bacterial sepsis-ARDS
group (P = 0.044). The mean (standard deviation)
APACHE II score, SOFA score and PaO2:FiO2 ratio
were similar in both groups (Table 1). The leukocyte
count, C-reactive protein and procalcitonin levels were
higher in the bacterial ARDS group than in the nvA
(H1N1)-ARDS group (P = 0.047, P =0 . 0 5a n dP <
0.001, respectively) (Table 2).
The results of the cytokine profile are shown in Figure
1. At admission, only IL-6, IL-12, IP-10 and TNFa were
significantly higher in the mild disease group than in
the control group. Except for IL-17 and IFNg,a l lc y t o -
kine levels were higher in critical patients with nvA
(H1N1)-ARDS than in the control group. Compared
with the mild disease group, significantly higher levels of
IL-6, IL-8, IL-15 and TNFa were found in the nvA
(H1N1)-ARDS group (P <0 . 0 0 1 ,P <0 . 0 0 1 ,P < 0.001
and P < 0.05, respectively). Compared with controls, the
levels of IL-6, IL-8, IL-9, IL-15, IL-17, IP-10 and TNFa
were significantly elevated in the bacterial sepsis-ARDS
group. Levels of IL-8, IL-17 and TNFa were significantly
higher in the bacterial-ARDS group versus the nvA
(H1N1)-ARDS group (P =0 . 0 5 ,P = 0.004 and P =
0.011, respectively; Figure 1).
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and mild disease) were stratified according to the inter-
val between symptom onset and admission. Levels of IL-
6, IL-8, IL-15 and IFNg were significantly higher in
patients with delayed admission, > 5 days after symptom
onset (P =0 . 0 0 6 ,P = 0.037, P = 0.013 and P = 0.027,
respectively) (Table 3).
Serum cytokine levels over time (3 days after admission
and antiviral treatment) showed a decrease of IL-6, IP-10,
TNFa,I F N g and IL-17 in critical patients with nvA
(H1N1)-ARDS (Table 4). Serum cytokine levels over time
in nvA(H1N1)-ARDS survivors showed a significant
decrease of IL-6, IP-10 and TNFa (Table 5). In nonsurvi-
vors versus survivors from the nvA(H1N1)-ARDS group,
Table 1 Demographic, co-morbidities and clinical characteristics of the patients
Characteristics of patients All patients with
nvA(H1N1)
infection
(n = 32)
nvA(H1N1)-ARDS
group (n = 21)
nvA(H1N1)-mild
disease group
(n = 11)
P value
a ARDS bacterial
sepsis group
(n = 20)
P value
b
Age (years) 37 (30.7 to 52) 42 (33.5 to 55.5) 33 (18 to 35) 0.009 57 (38.5 to 66) 0.12
Sex ratio (male/female) 16/16 9/12 7/4 0.4 8/12 1
Underlying disease
Cardiovascular disease 8 (25%) 6/21 2/11 0.6 8/20 0.5
Asthma/COPD 10 (31.25%) 8/21 2/11 0.4 12/20 0.2
Obesity (BMI > 30) 13 (40.6%) 12/21 1/11 0.01 3/20 0.01
Type 1 or 2 diabetes 2 (6.3%) 2/21 0 1/20 1
Esquizophrenia 3 (9.3%) 3/21 0 0
Cancer 3 (9.3%) 1/21 2/11 0.2 6/20 0.044
Pregnancy 3 (9.3%) 3/21 0 0
Interval between symptom onset and
hospital admission (days)
4.5 (2 to 7) 6 (3.5 to 8.5) 2 (2 to 3) 0.001 2 (0 to 3) 0.01
Presenting symptoms
Fever > 38°C 28 (87.5%) 18/21 10/11 1 18/20 1
Cough 32 (100%) 21/21 11/11 2/20
Dyspnea 25 (78%) 21/21 4/11 20/20
Myalgia 24 (75%) 14/21 10/11 0.2 0
SOFA score 6.1 (± 3.29) 7.2 (± 4.2) 0.5
APACHE II score 12.6 (± 6.62) 15.14 (± 6.36) 16.3 (± 6.03) 0.5
Respiratory condition
SaO2 < 94% 23 (71.8%) 21/21 2/11 20/20
PaO2:FiO2 ratio 1.96 (± 0.83) NA 1.72 (± 0.68) 0.28
Mechanical ventilation 11 (34.3%) 11/21 0 12/20 0.7
Non-invasive ventilation 10 (31.3%) 10/21 0 8/20 0.7
Initial chest X-ray scan
Extensive bilateral multilobar
infiltrates
21 (65.6%) 21/21 0 20/20
Complications
Secondary bacterial pneumonia 3 (9.4%) 2/21 1/11 4/20 0.4
Pneumothorax 3 (9.4%) 3/21 0 2/20 1
Encephalitis 1 (3.1%) 1/21 0 0
Acute renal failure requiring renal
replacement therapy
4 (12.5%) 4/21 0 3/20 1
Length of hospital stay (days) 10 (7 to 12.7) 11 (10 to 14) 6 (6 to 9) < 0.001 18 (13 to 41) 0.005
ICU length of stay (days) 4.5 (1 to 7.5) 7 (5 to 9) 0 16.5 (1 to 33) 0.3
In-hospital death 7 (21.8%) 7/21 0 3/20 0.2
Data presented as median (interquartile range), number (%) of patients, or mean (± standard deviation), unless otherwise indicated. APACHE, Acute Physiology
and Chronic Health Evaluation; ARDS, acute respiratory distress syndrome; BMI, body mass index; COPD, chronic obstructive pulmonary disease, ICU, intensive
care unit; NA, not applicable; nvA(H1N1), novel A(H1N1) virus; PaO2/FiO2, pressure of oxygen in arterial blood/fraction of inspired oxygen; SOFA, Sepsis-related
Organ Failure Assessment.
a differences in baseline characteristics between nvA(H1N1)-ARDS and nvA(H1N1)-mild disease (the Fisher exact test was used for categorical variables and Mann
Whitney test for continuous variables).
b differences in baseline characteristics between nvA(H1N1)-ARDS and bacterial sepsis-ARDS (the Fisher exact test was used for categorical variables and Mann
Whitney test for continuous variables).
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were significantly higher (Table 6). IL-17 was higher in
nonsurvivors 3 days after admission (Table 6).
Correlation between cytokine levels and clinical or
laboratory characteristics in patients with confirmed
nvA(H1N1) infection was determined by Spearman cor-
relation coefficient. We found significant correlation of
IL-6, IL-8 and IL-15 levels with C-reactive protein (r =
0.67, P < 0.001; r =0 . 5 ,P = 0.003; and r =0 . 4 8 ,P =
0.005, respectively), with PaO2:FiO2 ratio (r = -0.556,
P =0 . 0 0 1 ;r = -0.574, P < 0.001; and r = -0.614, P <
0.001, respectively) and with interval between symptom
onset and hospital admission (r =0 . 5 1 ,P = 0.002; r =
0.41, P = 0.019; and r = 0.48, P = 0.004, respectively).
IL-8 was significantly higher (P = 0.013) in obese ver-
sus nonobese patients with nvA(H1N1) infection.
Discussion
In this study we presented the cytokine profiles follow-
ing nvA(H1N1) infection in 32 hospitalized patients (11
mild and 21 severe disease) and the cytokine profiles
found in 20 cases of bacterial sepsis.
The patients with severe nvA(H1N1) disease were
younger than the patients with bacterial sepsis (no sta-
tistical significance). Similarly to other study groups, we
found that obesity was more common in the nvA
(H1N1) ARDS group, suggesting it may be a risk factor
for complications and admission to the ICU [2,5,6].
Laboratory findings in the same group of patients
include lymphocytopenia and elevation in levels of ala-
nine aminotransferase, aspartate aminotransferase, lac-
tate dehydrogenase and creatinine - as in other patient
groups with novel influenza virus infection [4,6]. In con-
trast, the bacterial-ARDS group presented no lymphocy-
topenia, lower elevation in serum liver enzymes and
higher levels of C-reactive protein and procalcitonin. No
significant differences were found between bacterial and
viral ARDS groups in SOFA and APACHE II scores at
admission. The pulmonary histopathological findings in
nvA(H1N1)-ARDS nonsurvivors were similar to other
fatal cases of nvA(H1N1) virus infection [12,13].
Installation of ARDS in the course of the disease was
the moment of blood sampling for cytokine measure-
m e n t s .T h e r ew a sad i f f e r e n c er e g a r d i n gt h et i m eo f
symptom onset and hospital admission between the
severe and mild groups of nvA(H1N1) disease that could
affect the comparison of cytokine levels between the two
groups. For this reason we not only compared the cyto-
kine levels between mild and severe disease, but also
mixed the patients with nvA(H1N1)-mild and severe dis-
ease and compared the level of cytokines according to
the interval between symptom onset and admission (first
interval 1 to 5 days, second interval 6 to 14 days). We
found that not all cytokines had the same behavior
against the time of symptom onset and admission.
The pattern of immune response in patients with nvA
(H1N1) virus infection is incompletely characterized.
CD4
+ T cells are known to play an important role in
the initiation of immune responses by providing help to
other cells. T-helper cells could be divided into subsets:
Th1, Th2 and Th17.
Th1 cells mainly develop following infections by intra-
cellular bacteria and some viruses [14]. The mediators
involved in the development of Th1 are IL-12, IFNg,
IL-15, IL-18 and TNFa.
IL-12 bridges the early nonspecific innate immunity
and the subsequent antigen-specific adaptative immunity
[15]. IL-12 was shown to inhibit apoptosis of T cells
[16] and of dendritic cells [17]. Alveolar macrophages
have a functional IL-12 receptor, and virus-infected
macrophages in the presence of IL-12 might be pro-
tected from apoptosis limiting viral clearance [18].
Table 2 Laboratory characteristics of the patients
Laboratory characteristic All patients with
nvA(H1N1) infection
(n = 32)
nvA(H1N1)-
ARDS group
(n = 21)
nvA(H1N1)-mild
disease group
(n = 11)
P value
a ARDS bacterial
sepsis group
(n = 20)
P value
b
Leukocyte count (x10
3/μl) 9.8 (7.5 to 11.8) 9.7 (8 to 12.3) 9.9 (6 to 10.5) 0.41 14.2 (8.2 to 20.5) 0.047
Lymphocyte count (x10
3/μl) 1.05 (0.7 to 1.87) 0.9 (0.6 to 1.3) 1.6 (0.9 to 2.5) 0.011 1.38 (1.12 to 2.9) 0.009
Platelet count (x10
3/μl) 218 (180 to 270) 218 (169 to 288) 218 (180 to 270) 0.7 241 (142.8 to 298) 0.8
C-reactive protein (mg/dl) 4.8 (1.2 to 9.6) 5.35 (4 to 10.2) 1.2 (0.6 to 4.4) 0.004 9.8 (5.75 to 22) 0.05
Procalcitonin (ng/ml) 0.23 (0.05 to 0.85) 0.39 (0.11 to 1.12) 0.06 (0.05 to 0.06) 0.003 6.3 (4.6 to 11.5) < 0.001
LDH (IU/l) 698 (360 to 980) 890 (618 to 1134) 360 (250 to 400) < 0.001 547 (408 to 812) 0.07
ALT (IU/l) 30.5 (17 to 80.75) 43 (21 to 92.5) 22 (15 to 30) 0.049 25 (13.5 to 50.75) 0.09
AST (IU/l) 42 (20 to 98) 95 (32.5 to 164) 17 (16 to 28) < 0.001 25 (20 to 656) 0.003
Total protein level (mg/dl) 6.75 (6 to 7.55) 6.2 (5.8 to 7) 8 (7 to 8) < 0.001 5.4 (4.8 to 6.4) 0.015
Creatinine level (mg/dl) 0.96 (0.6 to 1.17) 1.1 (0.9 to 1.25) 0.6 (0.5 to 0.8) < 0.001 1.55 (1 to 2.37) 0.11
Data presented as median (interquartile range). ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; LDH,
lactate dehydrogenase; nvA(H1N1), novel A(H1N1) virus.
aComparison between nvA(H1N1)-ARDS and nvA(H1N1)-mild disease (Mann-Whitney U test).
bComparison between nvA(H1N1)-ARDS and bacterial sepsis-ARDS (Mann-Whitney U test).
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effective mechanism for viral clearance [19]. Bermejo-
Martin and colleagues reported more significant IL-12
results in the critical A(H1N1) group of patients [9]. In
our study, IL-12 is significantly higher in the nvA
(H1N1)-mild disease group and in the nvA(H1N1)-
ARDS group versus the control group and is not signifi-
cantly higher in the bacterial ARDS group.
IL-15 plays a critical role in protecting CD8
+ Tc e l l s
from apoptosis during the contraction phase following
microbial infection [20,21]. The CD8
+ T cells surviving
i nt h ep r e s e n c eo fI L - 1 5m i g h tb ep a t h o g e n i ci nl u n g
injury following highly pathogenic influenza A virus
infection [22]. IL-15 activates the effector function of
memory phenotype CD8
+ cells [23]. In our study, IL-15
is significantly higher in the nvA(H1N1)-ARDS group
versus the nvA(H1N1)-mild disease group, but without
significant difference in the nvA(H1N1)-ARDS versus
bacterial-ARDS groups. Similar to our results, IL-15 was
a hallmark of critical illness in the Hong Kong and
Spanish nvA(H1N1) cytokine studies [8,9]. IL-15 is sig-
nificantly higher at admission (P1) and 3 days later (P2)
in the nvA(H1N1)-ARDS group for nonsurvivors versus
survivors, so it might be pathogenic in lung injury
Figure 1 Initial serum levels of cytokines in the four groups. The Mann-Whitney U test was used to compare cytokine levels: (A) IL-6. (B) IL-
8. (C) IL-9. (D) IL-12. (E) IL-15. (F) IL-17. (G) interferon-inductible protein-10 (IP-10). (H) IFNg. (I) TNFa. Data presented as median, quartiles, and
range. ARDS, acute respiratory distress syndrome; nvA(H1N1), novel A(H1N1) virus.
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found IL-15 significantly higher in critical A(H1N1)
patients and very significant in the A(H1N1)-ARDS
death group [8].
IFNg is a cytokine of innate and adaptative immunity.
Its major functions are activation of macrophages, dif-
ferentiation of Th1 from T cells, inhibition of the Th17
pathway and control of intracellular pathogens [24]. Ber-
mejo-Martin and colleagues found high systemic levels
of IFNg in hospitalized patients with nvA(H1N1) [9]. In
contrast, in the present study there were no differences
between the control and study groups. The IFNg level
over time in the nvA(H1N1) ARDS group was higher at
admission than 3 days later, without significant differ-
ence between survivors versus nonsurvivors.
TNFa is a cytokine of innate immunity. The principal
cellular targets and biologic effects include activation of
endothelial cells, neutrophil activation, fever, liver synth-
esis of acute phase proteins, muscle and fat catabolism,
and apoptosis of many cell types. In our study, we
found highly increased TNFa levels in the nvA(H1N1)-
mild disease, nvA(H1N1)-ARDS and bacterial ARDS
groups compared to the control group. TNFa is signifi-
cantly higher in nvA(H1N1)-ARDS versus nvA(H1N1)-
mild disease, with similar results being found by To and
colleagues and Bermejo-Martin and colleagues [8,9].
This cytokine is also significantly increased in bacterial-
ARDS versus nvA(H1N1)-ARDS.
For the groups of patients with nvA(H1N1), according
to the time interval between symptom onset and hospi-
tal admission, there were no significant differences
found for IL-12 and TNFa levels, but there were signifi-
cant differences for IL-15 and IFNg, levels being higher
when the time interval was between 6 and 14 days.
None of our patients were on oseltamivir medication
between symptom onset and admission.
Th17 cells are effective in host defense against certain
pathogens and tissue inflammation. Th17 mediators for
the development of Th17 cells are IL-6, transforming
growth factor beta, IL-8, IL-9, IL-17, IL-1 and IL-23.
IL-6 is a cytokine of innate immunity, its principal tar-
gets being the liver cells, the b cells and the naïve T cells
[25]. Despite the apparently beneficial role that macro-
phages play in controlling early viral replication, several
reports have demonstrated a more deleterious effect of
these cells in influenza A viral infections by excessive
inflammation in the lung attributed to IL-6 and TNFa
[26]. In our study, IL-6 is increased in nvA(H1N1)-ARDS
versus nvA(H1N1)-mild disease. Similarly, IL-6 and IL-
15 constituted a hallmark of critical illness in the Hong
Kong and Spanish nvA(H1N1) cytokine studies [8,9]. In
the nvA(H1N1)-ARDS group, the IL-6 serum level is sig-
nificantly higher at admission than 3 days later. In the
Table 3 Cytokine levels according to interval between
symptom onset and admission in 32 hospitalized nvA
(H1N1) patients
Interval
Cytokine
(pg/ml)
1 to 5 days 6 to 14 days P value
a
IL-6 9.8 (7.1 to 14.65) 18 (13.76 to 84.47) 0.006
IL-8 16.63 (9.4 to 41.12) 39.89 (20.62 to 79.84) 0.034
IL-9 9.9 (9.1 to 13.1) 11.5 (8.55 to 12.85) 1
IL-12 10.67 (7.11 to 17.8) 10.67 (8.89 to 17.8) 0.9
IL-15 3.9 (3.6 to 5) 6 (4.15 to 11.15) 0.013
IL-17 0.56 (0.323 to 0.98) 0.323 (0.323 to 3.68) 0.6
IP-10 66.85 (21.6 to 166) 60 (15.21 to 163.7) 0.7
IFNg 3.4 (2.965 to 3.4) 3.822 (3.4 to 5.625) 0.027
TNFa 4.15 (0.596 to 6.964) 4.15 (0.59 to 9.5) 0.3
Data presented as median (interquartile range). IP-10, interferon-inductible
protein-10; nvA(H1N1), novel A(H1N1) virus.
aThe Mann-Whitney test was used
to compare the cytokine levels.
Table 4 Serum cytokine levels over time in the nvA
(H1N1)-ARDS group (21 patients)
Cytokine
(pg/ml)
P1
a P2
b P value
c
IL-6 18 (10.41 to 64.88) 11 (8.09 to 23.77) 0.013
IL-8 40.14 (20.62 to 66.7) 24.47 (16.52 to 61.6) 0.18
IL-9 11.3 (9.05 to 14.25) 11.3 (9.65 to 14) 0.76
IL-12 10.67 (8.89 to 16.02) 14.24 (10.34 to 14.24) 0.9
IL-15 5.1 (4.15 to 8.35) 5 (3.9 to 7.7) 0.65
IL-17 0.98 (0.323 to 2.66) 0.323 (0.323 to 1.25) 0.049
IP-10 61.42 (20.5 to 274.5) 31.23 (9.19 to 49.19) 0.003
TNFa 4.15 (2.37 to 6.96) 0.596 (0.596 to 2.11) 0.001
IFNg 3.4 (3.18 to 5.43) 3.4 (2.96 to 3.82) 0.041
Data presented as median (interquartile range). IP-10, interferon-inductible
protein-10; nvA(H1N1), novel A(H1N1) virus. P1
aSerum cytokine levels at
admission.
P2
bSerum cytokines levels 3 days after admission.
cThe Wilcoxon test was
used to compare the cytokine levels.
Table 5 Serum cytokine levels over time in nvA(H1N1)-
ARDS survivors (14 patients)
Cytokine
(pg/ml)
P1
a P2
b P value
c
IL-6 14.76 (9.69 to 21.54) 8.73 (7.9 to 11.25) 0.02
IL-8 36.95 (16.75 to 41.49) 22.84 (14.6 to 46.86) 0.29
IL-9 10.6 (8.95 to 12.33) 11.3 (8.97 to 12.53) 0.45
IL-12 10.67 (7.11 to 14.24) 14.24 (9.78 to 15.13) 0.19
IL-15 4.55 (4.025 to 5.575) 4.7 (3.6 to 5.325) 0.4
IL-17 0.98 (0.323 to 1.146) 0.323 (0.323 to 0.323) 0.07
IP-10 57.26 (21.05 to 380.7) 29.67 (9.56 to 42.87) 0.01
TNFa 4.15 (3.26 to 6.96) 0.596 (0.596 to 1.485) 0.008
IFNg 3.4 (2.965 to 3.92) 3.4 (2.965 to 3.925) 0.3
Data presented as median (interquartile range). IP-10, interferon-inductible
protein-10; nvA(H1N1), novel A(H1N1) virus. P1
aSerum cytokine levels at
admission. P2
bSerum cytokine levels 3 days after admission.
cThe Wilcoxon
test was used to compare cytokine levels over time.
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Page 7 of 10same group, IL-6 is significantly higher in nonsurvivors
versus survivors at admission and 3 days later, which
seems to further contribute to pulmonary damage and
death. We found positive correlations between IL-6,
IL-15 and IL-8 levels and a longer than 5 days interval
between symptom onset and admission, as well as with
C-reactive protein, but a negative correlation with the
PaO2:FiO2 ratio, indicating the severity of the disease.
IL-8 is a chemokine of innate immunity. The chemo-
kine’s principal biologic effect is chemotaxis, being a
major chemokine for neutrophil activation, and migra-
tion into tissues [24]. In our study, IL-8 is highly signifi-
cant in the nvA(H1N1)-ARDS and ARDS bacterial
groups versus the control group, but is not significant in
mild disease. In contrast, IL-8 was increased in both cri-
tical and noncritical nvA(H1N1) hospitalized patients in
the Spanish and Hong Kong studies. In our study, IL-8
is higher in nvA(H1N1)-ARDS versus nvA(H1N1)-mild
disease and in bacterial ARDS versus nvA(H1N1)-
ARDS. The obese patients with nvA(H1N1) disease had
a significant level of IL-8. Plasma IL-8 levels are
increased in normoglycemic obese subjects, related to
fat mass and the TNFa system [27].
IP-10 is a chemokine of innate immunity, and macro-
phages and dendritic cells are the principal cell source.
We found a higher level of IP-10 in nvA(H1N1)-mild
disease, nvA(H1N1)-ARDS andb a c t e r i a l - A R D Sg r o u p s
versus the control group, and no other differences
between groups. In the nvA(H1N1)-ARDS group, the
IP-10 level is higher at admission than 3 days after
admission because of the survivors’ cytokine profile. An
increased level of IP-10 was found in the Spanish group
as early response to nvA(H1N1) infection in both hospi-
talized and mild patient disease, as in the present study,
while in the Hong Kong group IP-10 was significantly
higher in critical patients only. In our study, IP-10 levels
in nvA(H1N1)-ARDS nonsurvivors remained higher at
admission and 3 days later, being not significantly
correlated with the clinical outcome. Emphysema was
one of our hystopathological findings and thus it might
be speculated that a high level of IP-10 in nonsurvivors
could be correlated with emphysema. IP-10 released by
lung CD41 and CD81 T cells stimulates alveolar macro-
phage production of matrix metalloproteinase-12, which
digests lung elastin [28,29].
IL-17 is a cytokine of adaptative immunity. Principal
cellular targets include endothelial cells with increased
chemokine production and macrophages with increased
chemokine and cytokine production. This cytokine’s
principal biologic effect is proinflammatory [24,25].
In the present study IL-17 is significantly higher in the
bacterial ARDS group versus the control group and
is higher in the bacterial ARDS group versus the
nvA(H1N1)-ARDS group. No significant differences
between nvA(H1N1)-mild disease versus controls and
between nvA(H1N1)-ARDS versus controls were found.
In the nvA(H1N1)-ARDS group, IL-17 was higher at
admission and lower 3 days later. In the Spanish study
the IL-17 level was increased in hospitalized noncritical
patients, and in the Hong Kong study no differences
between groups were found, similar to the present
study.
IL-9, like IL-6, is a Th2 cytokine that induces differen-
tiation of Th17 cells and has anti-inflammatory proper-
ties. IL-9 is a cytokine of current interest associated
with allergic Th2 responses and is a key modulator of
antiviral immunity [30]. In our study IL-9 is significantly
higher in the H1N1-ARDS group versus the control
group, and is not significantly increased in mild disease
- in contrast to the Spanish study, where IL-9 was
increased in both critical and noncritical hospitalized
patients.
Regarding the behavior of Th17 mediators in nvA
(H1N1) groups of patients according to the time interval
between symptom onset and admission, there were no dif-
ferences for IL-9, IL-17 and IP-10 and there were
Table 6 Serum cytokine levels at admission and 3 days later in nvA(H1N1)-ARDS group survivors versus nonsurvivors
Cytokine (pg/ml) P1
a P2
b
Survivors Nonsurvivors P value
c Survivors Nonsurvivors P value
c
IL-6 14.76 (9.69 to 21.54) 64.76 (23.17 to 197.4) 0.025 8.73 (7.91 to 11.25) 26.9 (12 to 51.36) 0.005
IL-8 36.95 (16.75 to 41.49) 75.41 (36 to 148.3) 0.07 22.84 (14.6 to 46.86) 61 (17.44 to 89.8) 0.2
IL-9 10.6 (8.95 to 12.33) 13 (10.4 to 24.7) 0.12 11.3 (8.97 to 12.53) 14.5 (10.1 to 16.8) 0.2
IL-12 10.67 (7.11 to 14.24) 14.24 (10.67 to 17.8) 0.07 14.24 (9.78 to 15.13) 10.67 (10 to 14.24) 0.2
IL-15 4.55 (4.025 to 5.575) 10.6 (6.18 to 14.3) 0.006 4.7 (3.6 to 5.325) 10.4 (5.3 to 18.4) 0.012
IL-17 0.98 (0.323 to 1.146) 0.323 (0.323 to 4.373) 0.8 0.323 (0.323 to 0.323) 1.2 (0.323 to 1.645) 0.026
IP-10 57.26 (21.05 to 380.7) 99.87 (8.055 to 199.6) 0.9 29.67 (9.56 to 42.87) 40.2 (6.6 to 93.71) 0.5
TNFa 4.15 (3.262 to 6.964) 4.15 (0.596 to 11.89) 0.9 0.596 (0.596 to 1.485) 0.596 (0.596 to 2.12) 0.4
IFNg 3.4 (2.965 to 3.925) 5.43 (3.4 to 5.819) 0.19 3.4 (2.965 to 3.925) 3.7 (3 to 3.82) 0.5
Data presented as median (interquartile range). IP-10, interferon-inductible protein-10; nvA(H1N1), novel A(H1N1) virus. P1
aSerum cytokine levels at admission.
P2
bSerum cytokines levels 3 days after admission.
c comparison between survivors and nonsurvivors (Mann-Whitney U test).
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Page 8 of 10significant differences for IL-6 and IL-8, the levels being
higher when the interval was between 6 and 14 days. All
our patients with ARDS disease were on corticosteroid
treatment, because deficient corticosteroid-mediated
downregulation of inflammatory cytokine transcription in
ARDS patients is associated with disease progression and
mortality. Many studies reported that prolonged corticos-
teroid treatment was associated with a significant reduc-
tion in markers of systemic inflammation [31,32]. In the
present study the blood samples for cytokine measure-
ments were taken at admission for the bacterial-ARDS
group of patients, and at admission and 3 days later for
the nvA(H1N1) group of patients - for this reason, corti-
costeroid could not significantly affect cytokine levels.
The small number of patients enrolled in the mild dis-
ease group is one of our study limitations. Among hos-
pitalized patients with mild flu-like syndrome, only
those with risk of severe complications and of secondary
outbreaks in the exposed population were sampled for
real-time PCR. On the contrary, the laboratory of the
National Influenza Centre of Cantacuzino Institute,
Bucharest was overwhelmed, being the only centre for
influenza PCR diagnosis. Another limitation is the
exclusion of children, an important group with nvA
(H1N1) virus infection.
Conclusions
In our critically ill patients with nvA(H1N1) virus infec-
tion we found increased levels of some cytokines: IP-10,
TNFa, IL-15, IL-12, IL-6, IL-8 and IL-9. The hallmarks
for the severity of the disease were IL-6, IL-15, IL-8 and
TNFa. We found a positive correlation of IL-6, IL-15
and IL-8 with the admission delay and C-reactive pro-
tein and a negative correlation with the PaO2:FiO2 ratio.
The obese patients with nvA(H1N1) disease had a sig-
nificant level of IL-8. There were significant differences
in the level of cytokines when comparing viral ARDS
with bacterial ARDS.
Key messages
￿ In the influenza-related ARDS group, the levels of IL-
6, IL-8, IL-9, IL-12, IL-15, IP-10 and TNFa are signifi-
cantly increased versus the control group. In the bacter-
ial sepsis-ARDS group, levels of IL-6, IL-8, IL-9, IL-15,
IL-17, IP-10 and TNFa are also increased versus the
control group. When comparing these two groups, the
levels of IL-8, IL-17 and TNFa a r es i g n i f i c a n t l yh i g h e r
in bacterial ARDS versus viral ARDS, and IL-12 is
increased only in viral ARDS whereas IL-17 is increased
only in bacterial ARDS. When comparing the mild nvA
(H1N1) and critical ARDS influenza A groups, IL-6,
IL-8, IL-15 and TNFa are significantly higher in critical
ARDS patients being hallmarks of disease severity.
￿ The serum levels of IL-15, IL-6, IL-8 and IFNg
according to the interval between symptom onset and
admission in hospitalized nvA(H1N1) patients are signif-
icantly higher when this interval is longer than 5 days.
￿ In nonsurvivors versus survivors from the nvA
(H1N1)-ARDS group, IL-6 and IL-15 are increased at
admission and stay higher 3 days later - which seems to
further contribute to pulmonary damage and death.
￿ There is a positive correlation of IL-6, IL-8 and
IL-15 levels with C-reactive protein and with > 5-day
interval between symptom onset and hospital admission,
and a negative correlation with the PaO2:FiO2 ratio.
￿ The obese patients versus nonobese patients with
nvA(H1N1) infection have a significant level of IL-8.
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